Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWE-NEO: Nivolumab vs Nivolumab + Ipilimumab in Resectable Stage III Melanoma
NCT06794775Phase 3Recruiting
- Start
- Jul 2025
- Primary completion
- Apr 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ipilimumab in Malignant Melanoma (MM). Started Jul 2025; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06794775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794775.